Metabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case Report

A 71-year-old male ex-smoker presented in October 2021 to our department with a brain and bone metastatic adenocarcinoma NSCLC. PDL1, ROS, EGFR, and ALK were negative. He underwent stereotactic radiotherapy for brain metastases. In November 2021, he started a chemotherapy (CHT) regimen with cisplati...

Full description

Saved in:
Bibliographic Details
Main Authors: Alessia Surgo, Valerio Davì, Maria Paola Ciliberti, Roberta Carbonara, Morena Caliandro, Fiorella Cristina Di Guglielmo, Nicola Sasso, Roberto Calbi, Maria Annunziata Gentile, Tiziana Talienti, Isabella Bruno, Michele Troia, Ilaria Bonaparte, Giuseppe Mario Ludovico, Giammarco Surico, Alba Fiorentino
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Current Oncology
Subjects:
Online Access:https://www.mdpi.com/1718-7729/31/12/598
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846105150381359104
author Alessia Surgo
Valerio Davì
Maria Paola Ciliberti
Roberta Carbonara
Morena Caliandro
Fiorella Cristina Di Guglielmo
Nicola Sasso
Roberto Calbi
Maria Annunziata Gentile
Tiziana Talienti
Isabella Bruno
Michele Troia
Ilaria Bonaparte
Giuseppe Mario Ludovico
Giammarco Surico
Alba Fiorentino
author_facet Alessia Surgo
Valerio Davì
Maria Paola Ciliberti
Roberta Carbonara
Morena Caliandro
Fiorella Cristina Di Guglielmo
Nicola Sasso
Roberto Calbi
Maria Annunziata Gentile
Tiziana Talienti
Isabella Bruno
Michele Troia
Ilaria Bonaparte
Giuseppe Mario Ludovico
Giammarco Surico
Alba Fiorentino
author_sort Alessia Surgo
collection DOAJ
description A 71-year-old male ex-smoker presented in October 2021 to our department with a brain and bone metastatic adenocarcinoma NSCLC. PDL1, ROS, EGFR, and ALK were negative. He underwent stereotactic radiotherapy for brain metastases. In November 2021, he started a chemotherapy (CHT) regimen with cisplatin (75 mg/m<sup>2</sup> every 21 days) and pemetrexed (500 mg/m<sup>2</sup> every 21 days), and ICI with Atezolizumab (1200 mg every 21 days). In July 2022, RT to the lung tumor and mediastinal nodal was performed with a total dose of 45 Gy in 15 fractions. He continued with immunotherapy until December 2022, when a grade 3–4 toxicity from immunotherapy was observed (hypothyroidism, psoriasis, and cystitis). He achieved a complete clinical response to the therapy. To date, the patient is alive, with a complete metabolic response, without treatment at 37 months from diagnosis.
format Article
id doaj-art-91b7611fa1194d04a79907f4483cf087
institution Kabale University
issn 1198-0052
1718-7729
language English
publishDate 2024-12-01
publisher MDPI AG
record_format Article
series Current Oncology
spelling doaj-art-91b7611fa1194d04a79907f4483cf0872024-12-27T14:20:06ZengMDPI AGCurrent Oncology1198-00521718-77292024-12-0131128118812610.3390/curroncol31120598Metabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case ReportAlessia Surgo0Valerio Davì1Maria Paola Ciliberti2Roberta Carbonara3Morena Caliandro4Fiorella Cristina Di Guglielmo5Nicola Sasso6Roberto Calbi7Maria Annunziata Gentile8Tiziana Talienti9Isabella Bruno10Michele Troia11Ilaria Bonaparte12Giuseppe Mario Ludovico13Giammarco Surico14Alba Fiorentino15Radiation Oncology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyRadiation Oncology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyRadiation Oncology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyRadiation Oncology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyRadiation Oncology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyRadiation Oncology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyMedical Oncology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyRadiology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyRadiology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyRadiation Oncology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyNuclear Medicine Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyPathology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyRadiation Oncology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyUrology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyMedical Oncology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyRadiation Oncology Department, General Regional Hospital F. Miulli, 70021 Acquaviva delle Fonti, BA, ItalyA 71-year-old male ex-smoker presented in October 2021 to our department with a brain and bone metastatic adenocarcinoma NSCLC. PDL1, ROS, EGFR, and ALK were negative. He underwent stereotactic radiotherapy for brain metastases. In November 2021, he started a chemotherapy (CHT) regimen with cisplatin (75 mg/m<sup>2</sup> every 21 days) and pemetrexed (500 mg/m<sup>2</sup> every 21 days), and ICI with Atezolizumab (1200 mg every 21 days). In July 2022, RT to the lung tumor and mediastinal nodal was performed with a total dose of 45 Gy in 15 fractions. He continued with immunotherapy until December 2022, when a grade 3–4 toxicity from immunotherapy was observed (hypothyroidism, psoriasis, and cystitis). He achieved a complete clinical response to the therapy. To date, the patient is alive, with a complete metabolic response, without treatment at 37 months from diagnosis.https://www.mdpi.com/1718-7729/31/12/598NSCLCbrain metastasesimmunotherapycomplete responsecase report
spellingShingle Alessia Surgo
Valerio Davì
Maria Paola Ciliberti
Roberta Carbonara
Morena Caliandro
Fiorella Cristina Di Guglielmo
Nicola Sasso
Roberto Calbi
Maria Annunziata Gentile
Tiziana Talienti
Isabella Bruno
Michele Troia
Ilaria Bonaparte
Giuseppe Mario Ludovico
Giammarco Surico
Alba Fiorentino
Metabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case Report
Current Oncology
NSCLC
brain metastases
immunotherapy
complete response
case report
title Metabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case Report
title_full Metabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case Report
title_fullStr Metabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case Report
title_full_unstemmed Metabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case Report
title_short Metabolic Complete Response of Metastatic Oncogene-Negative, PDL1-Negative Non-Small Cell Lung Cancer After Chemo-Immunotherapy and Radiotherapy: A Case Report
title_sort metabolic complete response of metastatic oncogene negative pdl1 negative non small cell lung cancer after chemo immunotherapy and radiotherapy a case report
topic NSCLC
brain metastases
immunotherapy
complete response
case report
url https://www.mdpi.com/1718-7729/31/12/598
work_keys_str_mv AT alessiasurgo metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport
AT valeriodavi metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport
AT mariapaolaciliberti metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport
AT robertacarbonara metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport
AT morenacaliandro metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport
AT fiorellacristinadiguglielmo metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport
AT nicolasasso metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport
AT robertocalbi metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport
AT mariaannunziatagentile metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport
AT tizianatalienti metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport
AT isabellabruno metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport
AT micheletroia metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport
AT ilariabonaparte metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport
AT giuseppemarioludovico metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport
AT giammarcosurico metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport
AT albafiorentino metaboliccompleteresponseofmetastaticoncogenenegativepdl1negativenonsmallcelllungcancerafterchemoimmunotherapyandradiotherapyacasereport